Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response

British Journal of Cancer

Volumn 103, Issue 4, 2010, Pages 486-497

  Venkatasubramanian, R ^a   Arenas, R B ^b,c   Henson, M A ^a   Forbes, N S ^a,b  

^a University of Massachusetts Amherst   (United States)

^b Pioneer Valley Life Sciences Institute   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

dynamic contrast enhanced magnetic resonance imaging; predictive multiscale model; therapeutic response; tumour growth model; tumour heterogeneity

Indexed keywords

GADOLINIUM PENTETATE; PACLITAXEL;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST CANCER; CANCER GROWTH; CANCER PATIENT; CELL METABOLISM; CELL PROLIFERATION; CLINICAL ARTICLE; COMPUTER SIMULATION; DRUG DIFFUSION; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRIENT; PATIENT CARE; PRIORITY JOURNAL; TISSUE GROWTH;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMPUTER SIMULATION; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS;

EID: 77955514801     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605773     Document Type: Article

References (52)

1. Adam JA, Maggelakis SA (1990) Diffusion regulated growth characteristics of a spherical prevascular carcinoma. Bull Math Biol 52(4): 549-582
2. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, Stirling JJ, d'Arcy JA, Collins DJ, Pittam MR, Ravichandran D, Padhani AR (2008) Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14(20): 6580-6589
3. Araujo RP, McElwain DL (2004) A history of the study of solid tumour growth: the contribution of mathematical modelling. Bull Math Biol 66(5): 1039-1091
4. Bertuzzi A, D'Onofrio A, Fasano A, Gandolfi A (2003) Regression and regrowth of tumour cords following single-dose anticancer treatment. Bull Math Biol 65(5): 903-931
5. Buckley DL, Roberts C, Parker GJ, Logue JP, Hutchinson CE (2004) Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging-initial experience. Radiology 233(3): 709-715
6. Chen W, Giger ML, Bick U, Newstead GM (2006) Automatic identification and classification of characteristic kinetic curves of breast lesions on DCE-MRI. Med Phys 33(8): 2878-2887
7. Chuthapisith S, Eremin JM, El-Sheemy M, Eremin O (2006) Neoadjuvant chemotherapy in women with large and locally advanced breast cancer: chemoresistance and prediction of response to drug therapy. Surgeon 4(4): 211-219
8. Feng Y, Jeong EK, Mohs AM, Emerson L, Lu ZR (2008) Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn Reson Med 60(6): 1347-1352
9. Gardner SN (2000) A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and-nonspecific drugs. Cancer Res 60(5): 1417-1425
10. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Lacatelli A, Bonadonna G, Egorin MJ (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13(1): 180-190
11. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM (2002) MRI of the tumor microenvironment. J Magn Reson Imaging 16(4): 430-450
12. Groebe K (1995) An easy-to-use model for O2 supply to red muscle. Validity of assumptions, sensitivity to errors in data. Biophys J 68(4): 1246-1269
13. Harrer JU, Parker GJ, Haroon HA, Buckley DL, Embelton K, Roberts C, Baleriaux D, Jackson A (2004) Comparative study of methods for determining vascular permeability and blood volume in human gliomas. J Magn Reson Imaging 20(5): 748-757
14. Hawighorst H, Knapstein PG, Weikel W, Knopp MV, Zuna I, Knof A, Brix G, Schaeffer U, Wilkens C, Schoenberg SO, Essig M, Vaupel P, van Kaick G (1997) Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological micro-vessel density with correlation to lymphatic involvement. Cancer Res 57(21): 4777-4786
15. Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15(2): 154-163
16. Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93(4): 266-276
17. Hsiang DJ, Yamamoto M, Mehta RS, Su MY, Baick CH, Lane KT, Butler JA (2007) Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. Arch Surg 142(9): 855-861; discussion 860-861
18. Hylton N (2006) Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 24(20): 3293-3298 (Pubitemid 46622069)
19. Jackson TL, Byrne HM (2000) A mathematical model to study the effects of drug resistance and vasculature on the response of solid tumors to chemotherapy. Math Biosci 164(1): 17-38
20. Jain RK (1988) Determinants of tumor blood flow: a review. Cancer Res 48(10): 2641-2658
21. Jain RK (1998) The next frontier of molecular medicine: delivery of therapeutics. Nat Med 4(6): 655-657
22. Jain RK (1999) Transport of molecules, particles, and cells in solid tumors. Annu Rev Biomed Eng 1: 241-263
23. Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67(6): 2729-2735
24. Kim JJ, Tannock IF (2005) Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 5(7): 516-525
25. Konerding MA, Fait E, Gaumann A (2001) 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 84(10): 1354-1362
26. Krogh A (1919a) The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol 52(6): 409-415
27. Krogh A (1919b) The supply of oxygen to the tissues and the regulation of the capillary circulation. J Physiol 52(6): 457-474
28. Kuh HJ, Jang SH, Wientjes MG, Au JL (2000) Computational model of intracellular pharmacokinetics of paclitaxel. J Pharmacol Exp Ther 293(3): 761-770
29. Lonning PE (2007) Breast cancer prognostication and prediction: are we making progress? Ann Oncol 18(Suppl 8): viii3-viii7
30. Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters MJ, Gilhuijs KG (2008) Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol 191(5): 1331-1338
31. Mac Gabhann F, Ji JW, Popel AS (2006) Computational model of vascular endothelial growth factor spatial distribution in muscle and pro-angiogenic cell therapy. PLoS Comput Biol 2(9): e127
32. Mac Gabhann F, Popel AS (2005) Differential binding of VEGF isoforms to VEGF receptor 2 in the presence of neuropilin-1: a computational model. Am J Physiol Heart Circ Physiol 288(6): H2851-H2860
33. Martel AL (2006) A fast method of generating pharmacokinetic maps from dynamic contrast-enhanced images of the breast. Med Image Comput Comput Assist Interv 9(Part 2): 101-108
34. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, Gatti M, Biglia N, Sarotto I, Sismondi P, Regge D, Aglietta M (2004) Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat 83(1): 67-76
35. Mayr NA, Yuh WT, Jajoura D, Wang JZ, Lo SS, Montebello JF, Porter K, Zhang D, McMeekin DS, Buatti JM (2010) Ultra-early predictive assay for treatment failure using functional magnetic resonance imaging and clinical prognostic parameters in cervical cancer. Cancer 116(4): 903-912
36. Minchinton AI, Tannock IF (2006) Drug penetration in solid tumours. Nat Rev Cancer 6(8): 583-592
37. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239(2): 361-374
38. Prescott JW, Zhang D, Wang JZ, Mayr NA, Yuh WT, Saltz J, Gurcan M (2010) Temporal analysis of tumor heterogeneity and volume for cervical cancer treatment outcome prediction: preliminary evaluation. J Digit Imaging 23(3): 342-357
39. Sorensen AG (2006) Magnetic resonance as a cancer imaging biomarker. J Clin Oncol 24(20): 3274-3281
40. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK (2009) A 'vascular normalization index' as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 69(13): 5296-5300
41. Su MY, Cheung YC, Fruehauf JP, Yu H, Nalcioglu O, Mechetner E, Kyshtoobayeva A, Chen SC, Hsueh S, McLaren CE, Wan YL (2003) Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 18(4): 467-477
42. Tannock IF, Lee CM, Tunggal JK, Cowan DS, Egorin MJ (2002) Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin Cancer Res 8(3): 878-884
43. Thelwall PE, Neves AA, Brindle KM (2001) Measurement of bioreactor perfusion using dynamic contrast agent-enhanced magnetic resonance imaging. Biotechnol Bioeng 75(6): 682-690
44. Tofts PS (1997) Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7(1): 91-101
45. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17(2): 357-367
46. Turetschek K, Preda A, Novikov V, Brasch RC, Weinmann HJ, Wunderbaldinger P, Roberts TP (2004) Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. J Magn Reson Imaging 20(1): 138-144
47. Turnbull LW (2009) Dynamic contrast-enhanced MRI in the diagnosis and management of breast cancer. NMR Biomed 22(1): 28-39
48. Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49(23): 6449-6465
49. Venkatasubramanian R, Henson MA, Forbes NS (2006) Incorporating energy metabolism into a growth model of multicellular tumor spheroids. J Theor Biol 242(2): 440-453
50. Venkatasubramanian R, Henson MA, Forbes NS (2008) Integrating cell-cycle progression, drug penetration and energy metabolism to identify improved cancer therapeutic strategies. J Theor Biol 253(1): 98-117
51. Ward JP, King JR (1997) Mathematical modelling of avascular-tumour growth. IMA J Math Appl Med Biol 14(1): 39-69
52. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT (2007) Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy. Lancet Oncol 8(1): 63-74